ROS1 and metastatic neoplasm: In turn, this barrier to access may contribute to the development of clinical features (high order metastatic disease, brain metastases) or necessitate clinical decisions (use of non-targeted systemic therapies, targeted therapy initiation in final days of life) that may—and in the case of this ROS1-rearranged population, do—negatively impact outcome.